Loading
Loading
Triple-agonist next-generation incretin · GIP / GLP-1 / Glucagon
A next-generation triple-receptor agonist engaging GIP, GLP-1, and glucagon receptors simultaneously. The most-discussed metabolic research peptide of the decade - clinical Phase-2 research has reported the largest fat-mass reductions yet observed in this class, with a body-composition profile suggesting better preservation of lean mass compared to earlier-generation GLP-1 monotherapies.
Retatrutide (LY3437943) is a next-generation triple-receptor agonist (GIP / GLP-1 / glucagon) and the most-discussed metabolic research peptide of the decade.
Retatrutide (LY3437943) is a 39-amino-acid synthetic peptide developed by Eli Lilly. Published Phase-2 research (Jastreboff et al., New England Journal of Medicine, 2023) reported up to ~24% mean body-weight reduction at 48 weeks at the highest dose studied - substantially exceeding effects reported for semaglutide and tirzepatide monotherapy. The glucagon-receptor component is hypothesized to drive higher resting energy expenditure, contributing to the fat-mass-selective body composition profile observed.
CoA available on request
Every Retatrutide lot is independently tested in Dubai or the UK and documented with a signed Certificate of Analysis. To review the CoA for a specific lot, email support@caesarbiomedical.com with the lot number, or look it up on our verification page.
For laboratory research use only. Not intended for human or veterinary therapeutic use, diagnosis, or prevention of disease.
Have a question about a compound, its mechanism, or a lab report? Message us on WhatsApp and a member of the research team will reply - no forms, no sales script.
The research letter
One email per month. Citations included. Zero filler.